Skip to main content

Soft Tissue Injuries

1
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Teikoku Seiyaku
Teikoku SeiyakuJapan - Higashikagawa
1 program
1
Esflurbiprofen Hydrogel PatchPhase 21 trial
Active Trials
NCT04908748Completed200Est. Dec 2021
IBSA Institut Biochimique
IBSA Institut BiochimiqueSwitzerland - Lugano-Pazzallo
1 program
Licart™PHASE_31 trial
Active Trials
NCT05171673Completed151Est. Jul 2024

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
IBSA Institut BiochimiqueLicart™
Teikoku SeiyakuEsflurbiprofen Hydrogel Patch

Clinical Trials (2)

Total enrollment: 351 patients across 2 trials

Study of PK and Safety of the LicartTM Topical System in Pediatric and Adult Participants with Minor Soft Tissue Injury

Start: Oct 2021Est. completion: Jul 2024151 patients
Phase 3Completed
NCT04908748Teikoku SeiyakuEsflurbiprofen Hydrogel Patch

Efficacy and Safety of Esflurbiprofen Hydrogel Patch in the Treatment of Local Acute Pain

Start: May 2021Est. completion: Dec 2021200 patients
Phase 2Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.